A Phase 1b/2 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib (LANRA) in Combination With the FLT3 Inhibitor Gilteritinib, in Patients With FLT3-mutated Relapsed or Refractory AML

The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML).

Start Date05 Aug 2022

Sponsor / Collaborator

Kronos Bio, Inc.

NCT03285711 / CompletedPhase 2

A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)

The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (previously GS-9876) in adults with lupus membranous nephropathy (LMN).

Start Date06 Oct 2017

Sponsor / Collaborator

Gilead Sciences, Inc.

NCT03134222 / CompletedPhase 2

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).

Start Date24 May 2017

Sponsor / Collaborator

Gilead Sciences, Inc.

[+1]

100 Clinical Results associated with Lanraplenib

100 Translational Medicine associated with Lanraplenib

100 Patents (Medical) associated with Lanraplenib

Literatures (Medical) associated with Lanraplenib

01 Jul 2023·The Journal of investigative dermatology

Neutrophil-Specific Syk Expression Is Crucial for Skin Disease in Experimental Epidermolysis Bullosa Acquisita

Article

Author: Szilveszter, Kata P ; Balogh, Lili ; Németh, Tamás ; Káposztás, Eszter ; Mócsai, Attila

Autoantibodies against the dermal-epidermal junction component type VII collagen (C7) trigger skin disease in the inflammatory form of epidermolysis bullosa acquisita. We have previously identified the Syk tyrosine kinase as a crucial participant in anti-C7 antibody-induced experimental epidermolysis bullosa acquisita. However, it is still unclear which cellular lineage needs to express Syk during the disease process. In this study, we show that the loss of Syk, specifically from neutrophils, results in complete protection from the anti-C7 antibody-initiated skin disease both macroscopically and microscopically. Mice with a neutrophil-specific Syk deletion had decreased neutrophil accumulation and abrogated CXCL2 and IL-1β levels in the skin upon anti-C7 treatment, whereas isolated Syk-deficient neutrophils had decreased superoxide release, cell spreading, and cytokine release on C7-anti-C7 immune complex surfaces. Entospletinib and lanraplenib, two second-generation Syk-specific inhibitors, effectively abrogated immune complex-induced responses of human neutrophils and decreased the anti-C7 antibody-initiated, neutrophil-mediated ex vivo dermal-epidermal separation in human skin samples. Taken together, these results point to a crucial role for Syk in neutrophils in the development and progression of epidermolysis bullosa acquisita and suggest Syk inhibition as a potential therapeutic strategy.

28 Nov 2022·RheumatologyQ2 · MEDICINE

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study

Q2 · MEDICINE

Article

Author: Mozaffarian, Neelufar ; Gurtovaya, Oksana ; Bombardieri, Michele ; Mozaffarian, Afsaneh ; Mathur, Anubhav ; Pechonkina, Alena ; Price, Elizabeth ; Matzkies, Franziska ; Jiang, Wendy ; Kivitz, Alan ; Downie, Bryan ; Gottenberg, J Eric

Abstract:

Objective:

The aim of this study was to characterize the safety and efficacy of filgotinib, lanraplenib and tirabrutinib in patients with active SS.

Methods:

This multicentre, double-blind study randomized patients with active primary or secondary SS [EULAR SS disease activity index (ESSDAI) ≥5) to receive filgotinib 200 mg (Janus kinase-1 inhibitor), lanraplenib 30 mg (spleen tyrosine kinase inhibitor), tirabrutinib 40 mg (Bruton’s tyrosine kinase inhibitor), or placebo. The composite primary end point was the week-12 proportion of patients fulfilling protocol-specified improvement criteria (based on CRP and SS-related symptoms). The EULAR SS patient-reported index (ESSPRI) and the ESSDAI change from baseline (CFB) were secondary end points. Exploratory end points included disease-related biomarkers. Treatment-emergent adverse events (AEs) represented safety outcomes.

Results:

The mean of the baseline ESSDAI was 10.1, and of ESSPRI was 6.2 in the 150 patients who were treated; 125 completed the 24-week placebo-controlled treatment period. At week 12, 43.3% of the filgotinib group achieved the primary end point (P = 0.17 vs placebo) vs 42.3% (P = 0.16), 34.7% (P = 0.33), and 26.7% of lanraplenib, tirabrutinib, and placebo groups, respectively. Neither secondary end point was met. Biomarker reductions included immunoglobulins classically associated with SS disease activity. Filgotinib ESSDAI CFB appeared more pronounced in subgroups with baseline ESSDAI ≥14 or without DMARDs/CSs. Most AEs were Grade 1 or 2.

Conclusion:

Three drugs with disparate mechanisms were tested, but no significant differences vs placebo in primary or secondary end points were observed. These results may be considered hypothesis-generating, given the drug tolerability, subgroup analysis, and biomarker findings.

Trial registration:

ClinicalTrials.gov, https://clinicaltrials.gov, NCT03100942.

30 May 2022·RheumatologyQ2 · MEDICINE

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

Q2 · MEDICINE

Article

Author: Mozaffarian, Afsaneh ; Matzkies, Franziska ; Gurtovaya, Oksana ; Fleischmann, Roy ; Touma, Zahi ; Werth, Victoria P ; Wallace, Daniel ; Pechonkina, Alena ; Robern, Michael ; Downie, Bryan ; Tiamiyu, Iyabode

Abstract:

Objectives:

To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor, in cutaneous lupus erythematosus (CLE).

Methods:

This was a phase 2, randomized, double-blind, placebo-controlled, exploratory, proof-of-concept study of LANRA (30 mg), FIL (200 mg) or placebo (PBO) once daily for 12 weeks in patients with active CLE. At week 12, PBO patients were rerandomized 1:1 to receive LANRA or FIL for up to 36 additional weeks.

Results:

Of 47 randomized patients, 45 were treated (PBO, n = 9; LANRA, n = 19; FIL, n = 17). The primary endpoint [change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at week 12] was not met. The least squares mean CLASI-A score change from baseline was −5.5 (s.e. 2.56) with PBO, −4.5 (1.91) with LANRA and −8.7 (1.85) with FIL. Numerical differences between FIL and PBO were greater in select subgroups. A ≥5-point improvement in the CLASI-A score at week 12 was achieved by 50.0%, 56.3% and 68.8% in the PBO, LANRA and FIL arms, respectively. A numerically greater proportion of patients in the FIL arm (50%) also achieved ≥50% improvement in the CLASI-A score at week 12 (37.5% PBO, 31.3% LANRA). Most adverse events (AEs) were mild or moderate in severity. Two serious AEs were reported with LANRA and one with FIL.

Conclusion:

The primary endpoint was not met. Select subgroups displayed a numerically greater treatment response to FIL relative to PBO. LANRA and FIL were generally well tolerated.

Trial registration:

ClinicalTrials.gov identifier NCT03134222

News (Medical) associated with Lanraplenib

21 Mar 2024

·www.biospace.com

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence in the first half of 2025 $175.0 million in cash, cash equivalents and investments as of December 31, 2023, providing expected cash runway into the second half of 2026 SAN MATEO, Calif. and CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio Inc (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and fourth-quarter and full-year 2023 financial results. “In 2023, we made great progress across our portfolio and business. We demonstrated that KB-0742 has a safety pro is clearly differentiated from all other CDK9 inhibitors, and we believe our extended dosing schedule will show increased efficacy signals while maintaining a favorable safety profile,” said Nobert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio. “We also announced our second development candidate, KB-9558, which is designed to target the KAT domain of p300 and downregulate IRF4 transcription in multiple myeloma. We are looking forward to completing the IND-enabling studies in 2024 and expect to dose our first patients in the first half of 2025.” Clinical Program and Recent Company Updates KB-0742 At the 2023 AACR-NCI-EORTC International Conference, the Company reported target engagement, tumor regressions, and an acceptable safety pro KB-0742 dosed at 60mg three-days-on, four-days-off in heavily pre-treated patients with transcriptionally addicted solid tumors. Out of fourteen “all-comer” patients, two patients with myxoid liposarcoma exhibited tumor regressions: one (7th line) had a partial response (per RECIST v1.1) lasting 113 days and the second achieved a 26% reduction in tumor diameters with stable disease. KB-0742 also cleared the 80mg three-days-on, four-days-off schedule in dose escalation and is currently enrolling patients in the KB-0742 60mg four-days-on, three-days-off dose escalation cohort of the Phase 1/2 trial. At a medical conference in mid-2024, the Company intends to share an update on the clinical data to date from patients with transcriptionally addicted tumors who were dosed with 60mg three-days-on, four-days-off, and from “all-comer” patients in the dose-escalation cohort who received 80mg three-days-on, four-days-off. In the third quarter of 2024, the Company expects to clear the 80mg four-days-on, three-days-off dose escalation cohort, and begin enrolling patients in an expansion cohort including one or more of the following: non-small cell lung cancer, small cell lung cancer, ovarian cancer, and triple negative breast cancer. The Company expects to announce topline data from the expansion cohort at the 80mg four-days-on, three-days-off dose in the first half of 2025. KB-9558 In December 2023, the Company announced the nomination of KB-9558, a p300 KAT inhibitor, as a development candidate. KB-9558 is the second development candidate to emerge from Kronos Bio’s product engine, where the Company identified that inhibition of the lysine acetyltransferase (KAT) domain on p300 inhibits expression of interferon regulatory factor 4 (IRF4) and thus collapses the transcription regulatory network that is required for the survival of multiple myeloma cells. The Company plans to present data on KB-9558 at the American Association for Cancer Research (AACR) annual meeting, being held from April 5-10, 2024 in San Diego, California, including how targeting p300’s enzymatic KAT domain can selectively downregulate IRF4. Pending completion of IND-enabling studies in 2024, the Company intends to initiate a first-in-human trial in relapsed or refractory multiple myeloma in the first half of 2025. Lanraplenib In December 2023, after a review of data from the Phase 1b portion of its Phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the Company decided not to proceed to Phase 2. Company Update Kronos Bio extended its expected cash runway by a year, into the second half of 2026, through restructurings and resource optimization. Fourth-Quarter and Full-Year 2023 Financial Highlights Cash, Cash Equivalents and Investments: With its ongoing and currently planned clinical programs and $175.0 million in cash, cash equivalents and investments as of December 31, 2023, the Company anticipates sufficient resources to fund its planned operations into the second half of 2026. R&D Expenses: Research and development expenses were $18.7 million for the fourth quarter of 2023, which includes non-cash stock-based compensation expense of $2.5 million. For the full year of 2023, research and development expenses were $86.4 million, which includes non-cash stock-based compensation expense of $12.0 million. G&A Expenses: General and administrative expenses were $10.9 million for the fourth quarter of 2023, which includes non-cash stock-based compensation expense of $2.7 million. For the full year of 2023, general and administrative expenses were $41.7 million, which includes non-cash stock-based compensation expense of $13.0 million. Net Loss: Net loss for the fourth quarter of 2023 was $25.3 million, or $0.43 per share, including non-cash stock-based compensation expense of $5.2 million. Net loss for the full-year 2023 was $112.7 million, or $1.95 per share, including non-cash stock-based compensation expense of $25.0 million. About Kronos Bio, Inc. Kronos Bio is a biopharmaceutical company that is advancing an investigational CDK9 inhibitor compound, KB-0742, in a Phase 1/2 clinical trial as a treatment for MYC-amplified solid tumors and other transcriptionally addicted solid tumors as well as a preclinical development candidate, KB-9558, targeting the KAT domain of p300 for multiple myeloma. The Company’s scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit or follow the Company on LinkedIn. Forward-Looking Statements Statements in this press release that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release, in some cases, uses terms such as “anticipate,” “believe,” “could,” “expect,” “on track,” “plan,” “potential,” “promising,” “will,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kronos Bio’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Phase 1/2 study of KB-0742 being on track to clear 80mg four-days-on, three-days-off schedule in Q3 2024; expected clinical results from the KB-0742 study; the expected timing for additional clinical data from the Phase 1/2 KB-0742 study; the potential completion of IND-enabling studies and the initial of a clinical trial for KB-9558 and the timing thereof; future pipeline development activities or outcomes; the potential of Kronos Bio’s product candidates; Kronos Bio’s expected cash runway; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: risks associated with changes to the assumptions underlying estimated expenses and savings; changes in the macroeconomic environment or competitive landscape that impact Kronos Bio’s business; whether Kronos Bio will be able to progress its clinical trials on the timelines anticipated, including due to risks inherent in the clinical development of novel therapeutics; risks related to Kronos Bio’s limited experience as a company in conducting clinical trials; the risk that results of preclinical studies and early clinical trials (including preliminary results) are not necessarily predictive of future results; and risks associated with the sufficiency of Kronos Bio’s cash resources and need for additional capital. These and other risks are described in greater detail in Kronos Bio’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the SEC on November 13, 2023, and in its Annual Report on Form 10-K for the year ended December 31, 2023, being filed with the SEC today. Any forward-looking statements that are made in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Except as required by law, Kronos Bio assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Kronos Bio, Inc. Statements of Operations and Comprehensive Loss (in thousands, except per share data) (Unaudited) Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Revenue $ 2,286 $ — $ 6,288 $ — Operating expenses: Research and development 18,704 23,168 86,379 93,715 General and administrative 10,926 10,514 41,739 43,400 Total operating expenses 29,630 33,682 128,118 137,115 Loss from operations (27,344 ) (33,682 ) (121,830 ) (137,115 ) Other income (expense), net: Interest and other income, net 2,024 1,900 9,157 3,911 Total other income (expense), net 2,024 1,900 9,157 3,911 Net loss (25,320 ) (31,782 ) (112,673 ) (133,204 ) Other comprehensive income (loss): Net unrealized gain (loss) on available-for-sale securities 274 258 811 (753 ) Net comprehensive loss $ (25,046 ) $ (31,524 ) $ (111,862 ) $ (133,957 ) Net loss per share, basic and diluted $ (0.43 ) $ (0.56 ) $ (1.95 ) $ (2.37 ) Weighted-average number of shares used to compute net loss per share, basic and diluted 58,268 56,523 57,744 56,201 Kronos Bio, Inc. Selected Balance Sheet Data (in thousands) (Unaudited) December 31, 2023 December 31, 2022 Cash, cash equivalents and investments $ 174,986 $ 247,947 Total assets $ 213,279 $ 294,938 Total liabilities $ 54,201 $ 50,439 Total stockholders’ equity $ 159,078 $ 244,499 Investor & Media Contact: Margaux Bennett Vice President, Corporate Development and Investor Relations, Kronos Bio 650-781-5026 mbennett@kronosbio.com

Phase 1Financial StatementAACRExecutive ChangeClinical Result

25 Jan 2024

·www.fiercebiotech.com

Kronos calls time on CMO, CSO roles as part of C-suite shakeup

Replacing the three jettisoned C-suite roles will be four SPV positions overseeing: R&D; clinical development; corporate strategy and portfolio management; and corporate operations and legal. Kronos Bio had already trimmed back its headcount and pipeline in the wake of a mid-stage cancer flop. Now, it’s the company’s C-suite who are heading to the exits. The biotech has “eliminated three executive officer roles”—meaning Chief Medical Officer Jorge DiMartino, M.D., Chief Scientific Officer Christopher Dinsmore, Ph.D., and Chief Operating Officer and General Counsel Barbara Kosacz will all be out of a job. The company explained the changes were needed to ensure a “streamlined leadership structure designed to focus on pipeline advancement and align with Kronos Bio’s current operating needs.” The three executives will leave the company on Feb.16, although they will remain as strategic advisors for the business, according to a Jan. 25 press release. The leadership shakeup follows a headcount reduction of 19% in November in order to fund KB-0742, a CDK9 inhibitor currently in a phase 1/2 trial for solid tumors and non-Hodgkin lymphoma. A month after the layoffs, Kronos said it was discontinuing a cancer trial for lanraplenib and seeking a partner for the SYK inhibitor in the wake of a mid-stage trial flop. “This new leadership structure is designed to streamline our operations and reflects our ongoing effort to advance our pipeline, optimize our resources, and efficiently deliver on our business objectives,” CEO Norbert Bischofberger, Ph.D., said in the release. “I would like to thank Jorge, Chris, and Barbara for their leadership and dedication, and I wish them well in their future endeavors,” Bischofberger added. “They each built and managed strong teams, laying the groundwork for this new structure and preparing our future leaders for success.” Replacing the three jettisoned C-suite roles will be four SPV positions overseeing R&D; clinical development; corporate strategy and portfolio management; and corporate operations and legal. Those positions are filled by Charles Lin, Ph.D., Elizabeth Olek, Rocio Martin Hoyos and Allison Frisbee, respectively. Kronos said it expects to make savings from the changes, even after termination costs are accounted for. Besides KB-0742, Kronos has a partnership with Roche’s Genentech for several undisclosed discovery programs. Inked a year ago, the Genentech partnership is crucial for Kronos, coming right after the biotech kicked a late-stage AML asset called entospletinib to the curb. The Roche unit jumped in to save the day for the struggling biotech with a $20 million upfront payment plus milestones that could top $177 million for the first program and $100 million for the first licensed product. Kronos also recently revealed a new development candidate, dubbed KB-9558. The preclinical asset is designed to modulate the IRF4 transcription regulatory network—a key driver in multiple myeloma.

Executive Change

19 Dec 2023

·www.fiercebiotech.com

Kronos discontinues mid-stage AML trial after poor patient response

Lanraplenib is one of Kronos’ two clinical-stage assets. After a mid-stage flop, Kronos Bio is discontinuing a cancer trial for lanraplenib and seeking a partner to continue development of the SYK inhibitor—the second acute myeloid leukemia (AML) candidate to disappoint the biotech. The announcement, which was made last night after market close, sent the biotech’s stock spiraling 13%, from $1.47 per share yesterday to $1.27 as of 10:40 a.m. ET today. The pipeline update follows a review of phase 1b data from Kronos’ phase 1b/2 trial assessing lanraplenib in combo with Xospata among 24 patients with FLT3-mutated relapsed/refractory AML. The patients were split up across four groups, receiving 20 mg to 90 mg of lanraplenib in combination with 120 mg of Xospata. No complete responses (CRs) or CRs with partial hematologic recovery (CRh) were observed and several patients discontinued treatment early on, according to Kronos. The company has now chosen not to proceed with the phase 2 part of the trial but does want to continue development of lanraplenib with a partner. “Patients in our study were older, more heavily pre-treated, and frailer than the relapsed/refractory patients in earlier studies. Many patients experienced non-drug related infectious disease complications leading to discontinuation during the first two months of treatment without achieving the count recovery needed to achieve a CR or CRh,” Jorge DiMartino, M.D., Ph.D., chief medical officer and executive vice president of clinical development at Kronos, said in a Dec. 18 release. “Given the changes in the treatment landscape for relapsed/refractory FLT3-mutated AML, it would be challenging to demonstrate the clinical benefit of adding lanraplenib to gilteritinib in this population.” This summer, the FDA approved Daiichi Sankyo’s quizartinib (marketed as Vanflyta), the first FLT3 inhibitor approved across three phases of the common blood cancer. Lanraplenib is one of Kronos’ two clinical-stage assets. Attention will now turn to KB-0742, the company’s first internally discovered molecule. In November, the biotech shared positive preliminary phase 1/2 trial data for the solid tumor candidate and announced efforts to streamline operations that included a 19% workforce reduction. Besides KB-0742, Kronos has a partnership with Roche’s Genentech for several undisclosed discovery programs. Inked in January, the Genentech partnership is crucial for Kronos, coming right after the biotech kicked a late-stage AML asset called entospletinib to the curb. The Roche unit jumped in to save the day for the struggling biotech with a $20 million upfront payment plus milestones that could top $177 million for the first program and $100 million for the first licensed product. Now, after another AML disappointment, Kronos has revealed a new development candidate, dubbed KB-9558. The preclinical asset is designed to modulate the IRF4 transcription regulatory network—a key driver in multiple myeloma. KB-9558 is Kronos’ second internally created product and is currently in IND-enabling studies, which are expected to be completed in the fourth quarter of next year. “Existing therapies for this disease, including CAR-T and bispecific antibody therapies, are not curative, and there is substantial need for new therapies,” said Norbert Bischofberger, Ph.D., Kronos Bio president and CEO. “Preclinical data indicate that treatment of multiple myeloma cells with KB-9558 leads to a rapid and potent down-regulation of IRF4, and we believe our product candidate has the potential to be an innovative treatment for patients with this incurable disease.”

Phase 1Drug ApprovalPhase 2

100 Deals associated with Lanraplenib

External Link

KEGG	Wiki	ATC	Drug Bank
D11596	-	-	DB14770

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory acute myeloid leukemia	Phase 2	US	Kronos Bio, Inc.	05 Aug 2022
Refractory acute myeloid leukemia	Phase 2	ES	Kronos Bio, Inc.	05 Aug 2022
Relapsing acute myeloid leukemia	Phase 2	US	Kronos Bio, Inc.	05 Aug 2022
Relapsing acute myeloid leukemia	Phase 2	ES	Kronos Bio, Inc.	05 Aug 2022
Glomerulonephritis, Membranous	Phase 2	US	Gilead Sciences, Inc.	06 Oct 2017
Lupus Erythematosus, Cutaneous	Phase 2	US	Gilead Sciences, Inc.	24 May 2017
Lupus Erythematosus, Cutaneous	Phase 2	CA	Gilead Sciences, Inc.	24 May 2017
Sjogren's Syndrome	Phase 2	US	Gilead Sciences, Inc.	01 May 2017
Sjogren's Syndrome	Phase 2	PL	Gilead Sciences, Inc.	01 May 2017
Sjogren's Syndrome	Phase 2	ES	Gilead Sciences, Inc.	01 May 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03285711 (CTgov)	Phase 2	Glomerulonephritis, Membranous	9	Filgotinib placebo+Lanraplenib (Lanraplenib 30 mg)	dlavmqrcgm(clyhpxdwyd) = yldbmvjycs gfymlsddql (xntakbbwjz, xcyvpaulte - nphxpyebse) View more	-	18 May 2020
				Lanraplenib placebo+Filgotinib (Filgotinib 200 mg)	dlavmqrcgm(clyhpxdwyd) = lwlbrkthst gfymlsddql (xntakbbwjz, nemtngwfrb - ianwjtwfse) View more
NCT03134222 (CTgov)	Phase 2	Lupus Erythematosus, Cutaneous	47	Filgotinib placebo+Lanraplenib (Lanraplenib 30 mg)	mgvpvzoxaf(tmkradeaff) = yhfesefnnv mptgbyvrsb (hdvvilzgfa, xnkooygwnl - zauituufze) View more	-	08 Apr 2020
				Lanraplenib placebo+Filgotinib (Filgotinib 200 mg)	mgvpvzoxaf(tmkradeaff) = ydtjcvkoif mptgbyvrsb (hdvvilzgfa, dkygbkuznl - qrdkpvffcd) View more
NCT03100942 (CTgov)	Phase 2	Sjogren's Syndrome	152	Filgotinib placebo+Lanraplenib (Lanraplenib)	ekbeaondvu(tpskwlrnoi) = yhkehxlrrl jhhrterdiu (eynxcecvpr, skxuighnyk - xobxgqsjes) View more	-	22 Jan 2020
				Tirabrutinib placebo+Filgotinib (Filgotinib)	ekbeaondvu(tpskwlrnoi) = cwloweepmt jhhrterdiu (eynxcecvpr, mmpcfvezeg - avlfarjxxt) View more
NCT02959138 (CTgov)	Phase 1	Inflammation \| Cataract	36	lanraplenib (Cohort 1: Moderate Renal Impairment)	shondcoipe(mgapcftnik) = zbatfljoro nnuklvxlwq (qgjgqlzuin, qdotzaqolm - wewrcsmeqz) View more	-	25 Oct 2019
				lanraplenib (Cohort 1: Healthy Control)	shondcoipe(mgapcftnik) = osecvdhqmp nnuklvxlwq (qgjgqlzuin, zhervdqxzp - fsmwzyvzfi) View more
EULAR2019	Phase 2	Rheumatoid Arthritis DAS28(CRP) \| ACR20/50/70 \| HAQ-DI	83	GS-9876 10 mg	uqzcnofkiv(crnqmskaud) = ncqhjyyhwx toppmhvfia (focwzmolod )	-	12 Jun 2019
				GS-9876 30 mg	uqzcnofkiv(crnqmskaud) = ovnzmuahxw toppmhvfia (focwzmolod )
NCT02885181 (CTgov)	Phase 2	Rheumatoid Arthritis	83	GS-9876 placebo+Filgotinib+Methotrexate (Filgotinib)	pjntglrgks(xsmjdhxlrs) = kogybibnqb qragckbnmu (nhhdteatwo, cxskntdjcq - psnubkvcmg) View more	-	19 Sep 2018
				Filgotinib placebo+Methotrexate (Placebo)	pjntglrgks(xsmjdhxlrs) = aopdoeghex qragckbnmu (nhhdteatwo, rlyzwrpzrt - kosvokvlsr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis